真菌性外耳道炎患者感染真菌检出情况、耐药性及盐酸特比萘芬乳膏治疗对真菌转阴率的影响

doi:10.5246/jcps.2026.04.026

摘要/Abstract

摘要：

本研究旨在评估盐酸特比萘芬乳膏(THC)在治疗外耳道真菌感染中的效果, 包括真菌检测、耐药性以及其对真菌清除的影响。研究采用回顾性分析方法, 分析了2020年1月至2023年10月间治疗的126例患者。患者被分为两组: 对照组使用3%水杨酸醇溶液治疗, 研究组在使用该溶液的基础上加用THC治疗。对真菌清除率、临床症状、药物耐药性、不良反应及复发率进行评估。结果显示, 研究组的真菌清除率显著高于对照组(82.54% vs. 61.90%)。研究组的临床症状改善也较为显著, 且复发率较低(3.33% vs. 22.95%)。研究表明, THC与水杨酸醇溶液联合使用在治疗外耳道真菌感染中表现出良好的疗效及安全性。

关键词: 真菌性外耳道炎, 耐药性, 盐酸特比萘芬乳膏, 真菌转阴率, 抗真菌药物, 临床症状, 复发

Abstract:

This study aimed to evaluate fungal detection, antifungal drug resistance, and the therapeutic efficacy of terbinafine hydrochloride cream (THC) in promoting fungal clearance in patients with fungal otitis externa. A retrospective analysis was conducted on 126 patients treated between January 2020 and October 2023. Patients were assigned to a control group, receiving 3% salicylic acid alcohol solution, or a study group, receiving a combination of the solution and THC. Outcomes assessed included fungal clearance, clinical symptom improvement, drug resistance, adverse reactions, and recurrence rates. The results demonstrated that the study group achieved a significantly higher fungal clearance rate (82.54%) compared to the control group (61.90%). Additionally, patients in the study group showed more rapid symptom resolution and a markedly lower recurrence rate (3.33% vs. 22.95%). These findings indicated that the combination of THC and salicylic acid alcohol solution was an effective and well-tolerated treatment for fungal otitis externa.

Key words: Fungal otitis externa, Drug resistance, Terbinafine hydrochloride cream, Fungal clearance rate, Antifungal drugs, Clinical symptoms, Recurrence

Supporting:

吴有位, 陆英, 吴长明, 张锋. 真菌性外耳道炎患者感染真菌检出情况、耐药性及盐酸特比萘芬乳膏治疗对真菌转阴率的影响[J]. 中国药学(英文版), 2026, 35(4): 372-380.

Youwei Wu, Ying Lu, Changming Wu, Feng Zhang. Detection of fungal infections, drug resistance, and the impact of terbinafine hydrochloride cream treatment on fungal clearance rate in patients with fungal otitis externa[J]. Journal of Chinese Pharmaceutical Sciences, 2026, 35(4): 372-380.

图/表 5

Table 1. Clinical features.

Table 2. Fungal distribution (n (%)).

Table 3. Analysis of drug resistance in fungi (n (%)).

Table 4. Clinical symptoms (n (%)).

Table 5. Adverse reactions during treatment (n (%)).

参考文献 28

[1]	Ito, Y.; Inoue, N.; Kaneko, N.; Otsuka, M.; Yamasaki, S.; Yoshikawa, M. A case of fungal otitis externa caused by coinfection of Candida auris and Aspergillus flavus. J. Infect. Chemother. 2023, 29, 809–811.
[2]	Khribi, M.; El Abed, W.; Gnaba, K. Malignant otitis externa: a persistent challenge. La Tunis. Médicale. 2024, 102, 478–482.
[3]	Mostafa, M.G.; Ahmed, S.; Islam, M.R.; Rahman, M.A.; Khan, L.; Alam, M.M.; Ahmed, M.B. Efficacy of clotrimazole 1% solution compared to econazole nitrate 1% + triamcinolone acetonide 0.1% cream in patients with otomycosis. Mymensingh Med. J. 2021, 30, 638–643.
[4]	Jimenez-Garcia, L.; Celis-Aguilar, E.; Díaz-Pavón, G.; Muñoz Estrada, V.; Castro-Urquizo, Á.; Hernández-Castillo, N.; Amaro-Flores, E. Efficacy of topical clotrimazole vs. topical tolnaftate in the treatment of otomycosis. A randomized controlled clinical trial. Braz. J. Otorhinolaryngol. 2020, 86, 300–307.
[5]	Tang, W.; Wang, C. Bis-boric acid-mediated regioselective reductive aminolysis of 3,4-epoxy alcohols. J. Org. Chem. 2022, 87, 15653–15660.
[6]	Yassin, Z.; Amirzargar, B.; Ghasemi, R.; Valizadeh, F.; Fattahi, M. Comparison of acidifying agents and clotrimazole for treatment of otomycosis: a comprehensive one-way mini-review. Curr. Med. Mycol. 2023, 9, 45–51.
[7]	Nemati, S.; Gerami, H.; Faghih Habibi, A.; Kazemnejad, E.; Shabani, N.; Aghsaghloo, V.; Montazeri, S. Sertaconazole versus clotrimazole and miconazole creams in the treatment of otomycosis: a placebo-controlled clinical trial. Iran J. Otorhinolaryngol. 2022, 34, 27–34.
[8]	Xu, S.; Li, J.F.; Ding, L.; Gao, K.; Xie, F.Y.; Han, J.; Zhou, X.C. Efficacy and safety of terbinafine hydrochloride spray and 3% boric acid alcohol ear drops in otomycosis. Acta Oto Laryngol. 2020, 140, 302–306.
[9]	Peng, Y.X. Diagnosis and treatment of otitis externa mycotica: experiences with 216 cases. Chin. J. Otol. 2019, 17, 522–526.
[10]	Kong, W.X.; Zhou, L. Otorhinolaryngology-Head and Neck Surgery, 3rd ed.; People’s Medical Publishing House: Beijing. 2025, 116–117.
[11]	Medical Administration Department, Ministry of Health, PRC. National Guide to Clinical Laboratory Procedures, 3rd ed.; Southeast University Press: Nanjing. 2006, 126–137.
[12]	CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Clinical and Laboratory Standards Institute: Wayne, PA, 2017.
[13]	Sogebi, O.A.; Oyewole, E.A.; Osinupebi, O.A. Clinicopathological study of otomycosis in a tertiary hospital in South-west Nigeria. Afr Health Sci. 2024, 24, 69–75.
[14]	Hasnaoui, M.; Ben Mabrouk, A.; Chelli, J.; Larbi Ammari, F.; Lahmar, R.; Toumi, A.; Mighri, K. Necrotising otitis externa: a single centre experience. J. Otol. 2021, 16, 22–26.
[15]	Noroy, L.; Pujo, K.; Leghzali-Moise, H.; Saison, J. Aspergillus necrotizing otitis externa with temporomandibulozygomatic involvement. Eur. Ann. Otorhinolaryngol. Head Neck Dis. 2020, 137, 127–129.
[16]	Cheema, K.; Awan, N.; Raza, N.; Khan, K.; Qamar, S.; Ashraf, S. Association of Comorbid Conditions with Six-Month Survival and Disease Outcome in Patients of Necroinflammatory Otitis Externa. J. Coll. Physicians Surg. Pak. 2020, 30, 498–502.
[17]	Hao, X.K.; Zhou, J.; Li, N. Distribution and Drug Resistance of Fungal Pathogens in Patients with Otomycosis. Chin. Rem. Clin. 2022, 22, 21–23.
[18]	McCarty Walsh, E.; Hanson, M.B. Fungal infections of the external auditory canal and emerging pathogens. Otolaryngol. Clin. North Am. 2023, 56, 909–918.
[19]	Roohi, B.; Nemati, S.; Alipour, A.; Faeli, L.; Mayahi, S.; Haghani, I.; Shalchizadeh, M.; Darini, A.; Al-Hatmi, A.M.S.; Abastabar, M.; Shokohi, T. Otomycosis: The foremost aetiological agent causing otitis externa and the antifungal susceptibility pattern in North-Western Iran. Mycoses. 2023, 66, 87–97.
[20]	Jing, R.; Yang, W.H.; Xiao, M.; Li, Y.; Zou, G.L.; Wang, C.Y.; Li, X.W.; Xu, Y.C.; Hsueh, P.R. Species identification and antifungal susceptibility testing of Aspergillus strains isolated from patients with otomycosis in northern China. J. Microbiol. Immunol. Infect. 2022, 55, 282–290.
[21]	Gharaghani, M.; Halvaeezadeh, M.; Ali Jalaee, G.; Taghipour, S.; Kiasat, N.; Zarei Mahmoudabadi, A. Antifungal susceptibility profiles of otomycosis etiological agents in Ahvaz, Iran. Curr. Med. Mycol. 2020, 6, 18–22.
[22]	Kaminer, B.M.; El-Saied, S.; Lasry, B.; Kaplan, D.M. Diagnostic accuracy of eosinophil-to-lymphocyte ratio and eosinophil-to-neutrophil ratio as biomarkers for differentiating between fungal and bacterial infection in necrotising otitis externa. Clin. Otolaryngol. 2024, 49, 343–348.
[23]	Lee, J.S.; Lee, S.M.; Son, H.S.; Yoon, Y.N.; Shin, J.E.; Sul, W.J.; Yu, D.A.; Choe, Y.B.; Lee, Y.W. Analysis of the microbiome of the ear canal in normal individuals and patients with chronic otitis externa. Ann. Dermatol. 2022, 34, 461.
[24]	Du, Y.C.; Liu, H.H. Effect of terbinafine hydrochloride cream combined with 3% boric acid alcohol ear drops on fungal otitis externa. Chin. J. Mycol. 2022, 17, 227–230.
[25]	Peled, C.; Novoa, R.; El-Saied, S.; Sadeh, R.; Novack, V.; Kaplan, D.M. Computer tomography findings in necrotizing otitis externa based on the offending pathogens. Eur. Arch. Oto Rhino Laryngol. 2021, 278, 4707–4713.
[26]	Shang, L.M.; Liu, F.X.; Zhong, Y.Y.; Yu, J.F. Clinical curative effect of sodium bicarbonate for ear bath combined with triamcinolone econazole cream on fungal otitis externa and its influences on negative conversion ratio of fungi. Chin. J. Otorhinolaryngol. Integr. Med. 2021, 29, 422–424.
[27]	Kiakojuri, K.; Mahdavi Omran, S.; Roodgari, S.; Taghizadeh Armaki, M.; Hedayati, M.T.; Shokohi, T.; Haghani, I.; Javidnia, J.; Kermani, F.; Badali, H.; Abastabar, M. Molecular identification and antifungal susceptibility of yeasts and molds isolated from patients with otomycosis. Mycopathologia. 2021, 186, 245–257.
[28]	Sun, J.; Dai, W.B.; Liang, Z.; Wang, Z.Y.; Huang, C.S.; He, B.; Zhang, H.; Wang, X.Q.; Zhang, Q. Advances in the formulation and delivery technology of paclitaxel for injection. J. Chin. Pharm. Sci. 2015, 24, 487–500.